Keyphrases
Meta-analysis
100%
Breast Cancer Patients
100%
Confidence Interval
100%
Human Epidermal Growth Factor Receptor 2 (HER2)
100%
Systematic Meta-analysis
100%
Disease-free Survival
100%
Hormone Receptor
100%
Adjuvant Endocrine Therapy
100%
Human Epidermal Growth Factor Receptor 2-positive Breast Cancer
100%
No Significant Difference
66%
Randomized Controlled Trial
66%
Early Breast Cancer
66%
Hormone Receptor-positive
66%
Aromatase Inhibitors
66%
Therapeutic Approaches
33%
Adjuvant Therapy
33%
Tumor
33%
Hazard Ratio
33%
Random Effects Model
33%
Literature Search
33%
Precancerous Lesions
33%
Therapeutic Challenges
33%
Clinical Recommendations
33%
Hormonal Therapy
33%
Postmenopausal Patients
33%
Premenopausal Patients
33%
Neoadjuvant Endocrine Therapy
33%
ALTTO
33%
Adjuvant Endocrine Treatment
33%
Medicine and Dentistry
Meta-Analysis
100%
Systematic Review
100%
Hormone Receptor
100%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
100%
Adjuvant Endocrine Therapy
100%
Disease Free Survival
60%
Hormone Therapy
60%
Epidermal Growth Factor Receptor 2
60%
Gamma Urogastrone
60%
Randomized Controlled Trial
40%
Breast Cancer
40%
Tamoxifen
40%
Aromatase Inhibitor
40%
Disease
20%
Prospective Study
20%
Hazard Ratio
20%
Neoplasm
20%
Random Effects Model
20%
Adjuvant Therapy
20%
Pharmacology, Toxicology and Pharmaceutical Science
Endocrine Therapy
100%
Hormone Receptor
100%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
100%
Disease Free Survival
60%
Epidermal Growth Factor Receptor 2
60%
Gamma Urogastrone
60%
Randomized Controlled Trial
40%
Breast Cancer
40%
Tamoxifen
40%
Hormone Cancer Therapy
40%
Aromatase Inhibitor
40%
Disease
20%
Random Effects Model
20%
Neoplasm
20%
Prospective Study
20%
Biochemistry, Genetics and Molecular Biology
Epidermal Growth Factor Receptor
100%
Hormone Receptor
100%
Disease Free Survival
60%
Randomized Controlled Trial
40%
Aromatase Inhibitor
40%
Prospective Study
20%